PARP inhibitors trap the enzyme PARP on the DNA, creating a blockage that requires homologous recombination (HR) to repair. In BRCA-mutated tumours where HR is deficient, this becomes a lethal blockage for the cancer cells. My work sequencing Indian populations shows we have unique BRCA variants, and I worry the standard inhibitors may not be equally effective for all these mutations—lab models must reflect our genetic reality. Are we, in our urgency, sometimes applying global solutions without local validation, beta?
#exams#study
Jump in to reply — no account needed.